ArriVent BioPharma (AVBP) Competitors $24.50 +0.90 (+3.81%) Closing price 04:00 PM EasternExtended Trading$24.49 -0.01 (-0.02%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVBP vs. MLTX, CPRX, MTSR, CRNX, VKTX, MOR, SRRK, IMVT, HCM, and APLSShould you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include MoonLake Immunotherapeutics (MLTX), Catalyst Pharmaceuticals (CPRX), Metsera (MTSR), Crinetics Pharmaceuticals (CRNX), Viking Therapeutics (VKTX), MorphoSys (MOR), Scholar Rock (SRRK), Immunovant (IMVT), HUTCHMED (HCM), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry. ArriVent BioPharma vs. MoonLake Immunotherapeutics Catalyst Pharmaceuticals Metsera Crinetics Pharmaceuticals Viking Therapeutics MorphoSys Scholar Rock Immunovant HUTCHMED Apellis Pharmaceuticals MoonLake Immunotherapeutics (NASDAQ:MLTX) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk. Is MLTX or AVBP more profitable? MoonLake Immunotherapeutics' return on equity of -15.54% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets MoonLake ImmunotherapeuticsN/A -15.54% -15.09% ArriVent BioPharma N/A -43.89%-29.67% Does the MarketBeat Community prefer MLTX or AVBP? MoonLake Immunotherapeutics received 50 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 95.83% of users gave ArriVent BioPharma an outperform vote while only 82.02% of users gave MoonLake Immunotherapeutics an outperform vote. CompanyUnderperformOutperformMoonLake ImmunotherapeuticsOutperform Votes7382.02% Underperform Votes1617.98%ArriVent BioPharmaOutperform Votes2395.83% Underperform Votes14.17% Which has more risk and volatility, MLTX or AVBP? MoonLake Immunotherapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, ArriVent BioPharma has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Does the media favor MLTX or AVBP? In the previous week, MoonLake Immunotherapeutics had 6 more articles in the media than ArriVent BioPharma. MarketBeat recorded 11 mentions for MoonLake Immunotherapeutics and 5 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.14 beat MoonLake Immunotherapeutics' score of 0.50 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate MLTX or AVBP? MoonLake Immunotherapeutics presently has a consensus price target of $78.71, indicating a potential upside of 71.12%. ArriVent BioPharma has a consensus price target of $39.29, indicating a potential upside of 64.46%. Given MoonLake Immunotherapeutics' higher possible upside, equities research analysts clearly believe MoonLake Immunotherapeutics is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MoonLake Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Which has higher valuation and earnings, MLTX or AVBP? MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoonLake ImmunotherapeuticsN/AN/A-$36.01M-$2.30-20.00ArriVent BioPharmaN/AN/A-$69.33M-$3.77-6.34 Do insiders and institutionals have more ownership in MLTX or AVBP? 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 18.6% of ArriVent BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryMoonLake Immunotherapeutics beats ArriVent BioPharma on 9 of the 16 factors compared between the two stocks. Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVBP vs. The Competition Export to ExcelMetricArriVent BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$821.04M$6.85B$5.57B$8.66BDividend YieldN/A2.50%5.27%4.19%P/E Ratio-6.378.8827.3420.20Price / SalesN/A267.20415.29164.38Price / CashN/A65.8538.2534.64Price / Book-4.996.727.174.73Net Income-$69.33M$143.74M$3.23B$248.00M7 Day Performance3.32%12.24%6.74%4.53%1 Month Performance19.61%21.46%15.54%10.88%1 Year Performance28.63%9.88%32.85%15.20% ArriVent BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVBPArriVent BioPharma1.4191 of 5 stars$24.50+3.8%$39.29+60.3%+27.2%$838.22MN/A-6.5040Positive NewsMLTXMoonLake Immunotherapeutics2.1072 of 5 stars$47.51+15.4%$78.71+65.7%+11.9%$3.04BN/A-36.832Analyst RevisionHigh Trading VolumeCPRXCatalyst Pharmaceuticals4.6496 of 5 stars$24.87-0.1%$32.29+29.8%+65.4%$3.03B$534.65M21.0880MTSRMetseraN/A$28.67+2.0%$47.00+63.9%N/A$3.01BN/A0.0081Trending NewsAnalyst ForecastGap UpCRNXCrinetics Pharmaceuticals3.6137 of 5 stars$31.90+0.1%$74.56+133.7%-27.8%$2.99B$760,000.00-8.55210Positive NewsAnalyst RevisionVKTXViking Therapeutics4.563 of 5 stars$26.08-0.2%$87.15+234.2%-50.8%$2.93BN/A-26.0820Options VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SRRKScholar Rock4.1221 of 5 stars$29.23-1.8%$42.67+46.0%+258.3%$2.78B$33.19M-12.44140IMVTImmunovant1.4327 of 5 stars$15.36-0.3%$38.33+149.6%-35.3%$2.61BN/A-5.86120Positive NewsAnalyst RevisionHCMHUTCHMED1.4425 of 5 stars$14.29+5.1%$19.00+33.0%-10.1%$2.49B$630.20M0.001,760APLSApellis Pharmaceuticals4.6354 of 5 stars$19.21+0.4%$40.05+108.5%-52.0%$2.41B$775.84M-9.46770Analyst Revision Related Companies and Tools Related Companies MoonLake Immunotherapeutics Competitors Catalyst Pharmaceuticals Competitors Metsera Competitors Crinetics Pharmaceuticals Competitors Viking Therapeutics Competitors MorphoSys Competitors Scholar Rock Competitors Immunovant Competitors HUTCHMED Competitors Apellis Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVBP) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored50-year legend: Here’s exact day stocks will crashGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
